Precede Biosciences raised $83.5 million in Series B financing plus a $20 million credit facility to expand its liquid biopsy platform for pharma partnerships and clinical trials. The Boston company profiles genome‑wide expression of cancer surface proteins from blood using NGS and machine learning. Precede said the new capital will scale capacity and support collaborations across roughly 30 drug programs, targeting ADCs, radiopharmaceuticals and other precision medicines. Investors include Labcorp Venture Fund, UPMC Enterprises, Illumina Ventures, Bristol Myers Squibb and others. Precede positions its assay as a translational tool for patient selection, mechanism‑of‑response studies and biomarker development — functions that drug developers increasingly demand during clinical and regulatory planning.